CD19 and diffuse large B-cell lymphoma: CD19 antibody conjugated to tesirine, a pyrrolobenzodiazepine dimer (PBDD) cytotoxin, loncastuximab-tesirine (LT), demonstrated promising clinical activity in prognostically adverse R/R DLBCL including double-hit and transformed lymphoma in the LOTIS-2 clinical trial [44].